These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32516368)

  • 21. Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles.
    Castanheira M; Collingsworth TD; Davis AP; Deshpande LM; Pfaller MA
    Mycoses; 2021 Oct; 64(10):1279-1290. PubMed ID: 33705591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home Environment as a Source of Life-Threatening Azole-Resistant Aspergillus fumigatus in Immunocompromised Patients.
    Lavergne RA; Chouaki T; Hagen F; Toublanc B; Dupont H; Jounieaux V; Meis JF; Morio F; Le Pape P
    Clin Infect Dis; 2017 Jan; 64(1):76-78. PubMed ID: 27682064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators.
    Jørgensen KM; Guinea J; Meletiadis J; Hare RK; Arendrup MC
    J Antimicrob Chemother; 2020 Sep; 75(9):2573-2581. PubMed ID: 32556315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
    Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
    J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients.
    Fischer J; van Koningsbruggen-Rietschel S; Rietschel E; Vehreschild MJ; Wisplinghoff H; Krönke M; Hamprecht A
    J Antimicrob Chemother; 2014 Jun; 69(6):1533-6. PubMed ID: 24486872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.
    Wang Y; Zhang L; Zhou L; Zhang M; Xu Y
    Front Public Health; 2022; 10():835092. PubMed ID: 35493371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.
    Meis JF; Chowdhary A; Rhodes JL; Fisher MC; Verweij PE
    Philos Trans R Soc Lond B Biol Sci; 2016 Dec; 371(1709):. PubMed ID: 28080986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
    Buil JB; Brüggemann RJM; Wasmann RE; Zoll J; Meis JF; Melchers WJG; Mouton JW; Verweij PE
    J Antimicrob Chemother; 2018 Jan; 73(1):134-142. PubMed ID: 29048485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.
    Lestrade PPA; Buil JB; van der Beek MT; Kuijper EJ; van Dijk K; Kampinga GA; Rijnders BJA; Vonk AG; de Greeff SC; Schoffelen AF; van Dissel J; Meis JF; Melchers WJG; Verweij PE
    Emerg Infect Dis; 2020 Jul; 26(7):1447-1455. PubMed ID: 32568033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States.
    Wiederhold NP; Gil VG; Gutierrez F; Lindner JR; Albataineh MT; McCarthy DI; Sanders C; Fan H; Fothergill AW; Sutton DA
    J Clin Microbiol; 2016 Jan; 54(1):168-71. PubMed ID: 26491179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
    Krishnan-Natesan S; Wu W; Chandrasekar PH
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.
    Mavridou E; Meletiadis J; Rijs A; Mouton JW; Verweij PE
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1738-44. PubMed ID: 25583716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of Azole Resistance in Aspergillus.
    Wiederhold NP; Patterson TF
    Semin Respir Crit Care Med; 2015 Oct; 36(5):673-80. PubMed ID: 26398534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes.
    Jensen RH; Hagen F; Astvad KM; Tyron A; Meis JF; Arendrup MC
    Clin Microbiol Infect; 2016 Jun; 22(6):570.e1-9. PubMed ID: 27091095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated Prevalence of Azole-Resistant Aspergillus fumigatus in Urban versus Rural Environments in the United Kingdom.
    Sewell TR; Zhang Y; Brackin AP; Shelton JMG; Rhodes J; Fisher MC
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Center Evaluation of an Agar-Based Screening for Azole Resistance in Aspergillus fumigatus by Using VIPcheck.
    Buil JB; van der Lee HAL; Rijs AJMM; Zoll J; Hovestadt JAMF; Melchers WJG; Verweij PE
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.
    Chowdhary A; Sharma C; Hagen F; Meis JF
    Future Microbiol; 2014; 9(5):697-711. PubMed ID: 24957095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species.
    Serrano-Lobo J; Gómez A; Rodríguez-Sánchez B; Muñoz P; Escribano P; Guinea J;
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048221. PubMed ID: 34252311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.